UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors

Journal of rheumatology, 2012-06, Vol.39 (6), p.1179-1184

2012

Volltextzugriff (PDF)

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

International Journal of Rheumatology, 2014-01, Vol.2014 (2014), p.t1-9

2014

Volltextzugriff (PDF)

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.39-46

2011

Volltextzugriff (PDF)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.922-929

2009

Volltextzugriff (PDF)

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

Rheumatology (Oxford, England), 2010-09, Vol.49 (9), p.1683-1693

2010

Volltextzugriff (PDF)

Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey

Journal of rheumatology, 2008-02, Vol.35 (2), p.270

2008

Volltextzugriff (PDF)

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)

Journal of rheumatology, 2008-07, Vol.35 (7), p.1346

2008

Volltextzugriff (PDF)

GISEA: an Italian biological agents registry in rheumatology

Reumatismo, 2011-11, Vol.63 (3), p.155-164

2011

Volltextzugriff (PDF)

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching

Annals of the rheumatic diseases, 2020-02, Vol.79 (2), p.e13-e13

2020

Volltextzugriff (PDF)

Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Annals of the rheumatic diseases, 2019-04, Vol.78 (4), p.e23-e23

2019

Volltextzugriff (PDF)

Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance

Journal of rheumatology. Supplement, 2014-05, Vol.91, p.47-55

2014

Volltextzugriff (PDF)

Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke

Annals of the rheumatic diseases, 2019-04, Vol.78 (4), p.e25-e25

2019

Volltextzugriff (PDF)

Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations

Journal of rheumatology. Supplement, 2014-05, Vol.91, p.41-46

2014

Volltextzugriff (PDF)

Response to: ‘Seeing the glass either half full or half empty: response to the correspondence ’Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?'' by Scherlinger and Schaeverbeke

Annals of the rheumatic diseases, 2018-02, p.annrheumdis-2018-213044

2018

Volltextzugriff (PDF)

Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries

Journal of rheumatology. Supplement, 2014-05, Vol.91, p.56

2014

Volltextzugriff (PDF)

Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study

Rheumatology (Oxford, England), 2007-07, Vol.46 (7), p.1161-1164

2007

Volltextzugriff (PDF)

Focus on biosimilar etanercept - bioequivalence and interchangeability

Biologics, 2018-01, Vol.12, p.87-95

2018

Volltextzugriff (PDF)

Uveitis in Spondyloarthritis: An Overview

Journal of rheumatology. Supplement, 2015-11, Vol.93, p.27-29

2015

Volltextzugriff (PDF)

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Seminars in arthritis and rheumatism, 2017-10, Vol.47 (2), p.183-192

2017

Volltextzugriff (PDF)

Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment

Journal of rheumatology. Supplement, 2014-05, Vol.91, p.78-82

2014

Volltextzugriff (PDF)

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Rheumatology (Oxford, England), 2015-05, Vol.54 (5), p.792-797

2015

Volltextzugriff (PDF)

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study

Annals of the rheumatic diseases, 2019-10, Vol.78 (10), p.1444-1446

2019

Volltextzugriff (PDF)

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis

Clinical and experimental immunology, 2019-04, Vol.196 (1), p.123-138

2019

Volltextzugriff (PDF)

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials

Rheumatology (Oxford, England), 2024-02

2024

Volltextzugriff (PDF)

Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study

Clinical and Experimental Rheumatology, 2021-09, Vol.39 (5), p.961-969

2021

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Aktive Filter

ThemaRheumatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(150)

Sprache

Englisch
(149)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(147)
Science & Technology
(147)
Humans
(138)
Male
(84)
Female
(79)
Biological And Medical Sciences
(68)
Medical Sciences
(68)
Middle Aged
(63)
Adult
(53)
Aged
(51)
Diseases Of The Osteoarticular System
(45)
Inflammatory Joint Diseases
(36)
Treatment Outcome
(34)
Psoriatic Arthritis
(29)
Antirheumatic Agents - Therapeutic Use
(25)
Antibodies, Monoclonal - Therapeutic Use
(24)
Magnetic Resonance Imaging
(23)
Prospective Studies
(20)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(20)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)

GISEA: an Italian biological agents registry in rheumatology

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching

Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance

Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke

Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations

Response to: ‘Seeing the glass either half full or half empty: response to the correspondence ’Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?'' by Scherlinger and Schaeverbeke

Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries

Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study

Focus on biosimilar etanercept - bioequivalence and interchangeability

Uveitis in Spondyloarthritis: An Overview

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials

Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study

Aktive Filter

Suchergebnisse filtern